Yamamoto Yoshiyuki

ヤマモトヨシユキ | Yamamoto Yoshiyuki

Affiliation and department：
Job title： Assistant professor
Research theme for competitive and other funds (4)：

2023 - 2026 尿路上皮癌のRNA修飾によるエピトランスクリプトムの解明と新規治療戦略創成
2020 - 2023 Evolution of the mutational profile of circulating tumor DNA in renal cancer and its clinical application to personalized medicine
2018 - 2020 Elucidation of shorten mechanism and detection of mutations for circulating tumor DNA in renal cell carcinoma patients.
2016 - 2018 Clinical application of circulating-tumor DNA for renal cell carcinoma.

Papers (66)：

Akinaru Yamamoto, Atsunari Kawashima, Shinsuke Sakai, Masashi Mita, Nesrine Sassi, Shunsuke Inoguchi, Yuki Horibe, Akihiro Yoshimura, Masaru Tani, Liu Yutong, et al. Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma. Biochemical and biophysical research communications. 2024. 733. 150701-150701
Taketo Kawai, Mizuki Onozawa, Satoru Taguchi, Masaki Shiota, Shinichi Sakamoto, Yoshiyuki Yamamoto, Yasuhide Kitagawa, Tohru Nakagawa, Shiro Hinotsu, Haruki Kume. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study. Japanese journal of clinical oncology. 2024. 54. 9. 1045-1051
Akihiro Yoshimura, Taigo Kato, Yasutomo Nakai, Masao Tsujihata, Shingo Toyoda, Mototaka Sato, Kyosuke Matsuzaki, Wataru Nakata, Tetsuya Takao, Syunsuke Inoguchi, et al. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan. International journal of clinical oncology. 2024. 28回・37回. 137-137
Atsunari Kawashima, Yu Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Norio Nonomura. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution. International journal of clinical oncology. 2024. 29. 8. 1096-1104
Tokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, Dai Takamatsu, Yoshiyuki Matsui, Akira Yokomizo, Ryoichi Saito, Shuichi Morizane, Makito Miyake, Masakazu Tsutsumi, et al. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. International journal of clinical oncology. 2024. 29. 10. 1586-1593

ｍore...

MISC (282)：

山道岳, 加藤大悟, 荒川憲昭, 氏家剛, 本山雄一, 王谷英達, 明庭昇平, 石津谷祐, 山本致之, 波多野浩士, et al. GDPPはvicious cycleを亢進させて骨転移を有する去勢抵抗性前立腺癌における血中骨転移バイオマーカーとなる. 泌尿器外科. 2024. 37. 8. 892-893
植村俊彦, 河嶋厚成, 神宮司健太郎, 元岡大祐, ネスリン・サッシ, 岡利樹, 奥田洋平, 山本顕生, 山道岳, 冨山栄輔, et al. 血中細胞外小胞内の細菌由来DNAは腎癌診断および免疫治療予後予測マーカーとなる. 腎癌研究会会報. 2024. 54. 116-116
加藤大悟, 石津谷祐, 山本致之, 波多野浩士, 河嶋厚成, 三善英知, 野々村祝夫. 血清フコシル化ハプトグロビン値は免疫チェックポイント阻害薬の有用な奏効予測マーカーとなる. 腎癌研究会会報. 2024. 54. 116-116
武田健, 石津谷祐, 山本致之. 経尿道的前立腺吊上術後に生じたGrade3a合併症(Clavien-Dindo分類)の経験. 泌尿器外科. 2024. 37. 臨増. 763-763
加藤大悟, 石津谷祐, 山本致之, 波多野浩士, 河嶋厚成, 野々村祝夫. 転移性腎細胞癌患者における免疫チェックポイント阻害剤投与による内分泌系irAEと臨床予後との関連性. 日本内分泌学会雑誌. 2024. 100. 1. 308-308

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page